Trial Search Results

Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer

To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening program.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


Inclusion Criteria:

   - For both experimental subjects and controls:

      1. Patients between older than 18 years of age of all ethnic backgrounds and

      2. Patients with chronic liver disease

   - For Experimental Subjects Only:

      1. Patients with HCC with a hepatic mass larger or equal to 5cm

      2. Patients with HCC with a hepatic mass lesion confirmed by fine needle aspirate
      (FNA) or by pathology in the cases of surgical resection

      3. Patients with HCC with a hepatic mass lesion with characteristic CT or MRI or
      angiographic appearance.

   - For Controls Only:

Patients with chronic liver disease without evidence of HCC confirmed by either :

1. A normal AFP level

2. a negative imaging study (ultrasound, CT, or MR imaging).

3. Negative liver cancer on explants.

*Exclusion Criteria:

   1. Patients who declined to participate in the study

   2. Patients with a history of HIV infection

   3. Patients with concurrent advanced malignancy of non-hepatic origin.

   4. Patients with significant use of androgenic steroid.

   5. Patients with exposure to vinyl chloride.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Linder